[
  {
    "ts": null,
    "headline": "Can Amgen Sustain Its Rally In 2026",
    "summary": "Amgen Inc. raises 2025 revenue guidance on strong Repatha and Imdelltra sales and dividend hike. Click for this AMGN update.",
    "url": "https://finnhub.io/api/news?id=3206d8bcffd059c1f673da6ff56b46640d3bb167e099f635b7cf60fcdeed5ba9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766754208,
      "headline": "Can Amgen Sustain Its Rally In 2026",
      "id": 137908908,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1023666022/image_1023666022.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Amgen Inc. raises 2025 revenue guidance on strong Repatha and Imdelltra sales and dividend hike. Click for this AMGN update.",
      "url": "https://finnhub.io/api/news?id=3206d8bcffd059c1f673da6ff56b46640d3bb167e099f635b7cf60fcdeed5ba9"
    }
  },
  {
    "ts": null,
    "headline": "Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access",
    "summary": "US price cuts, Medicare expansion, and new oral GLP-1 approvals reshape the competitive outlook for weight-loss drugs.",
    "url": "https://finnhub.io/api/news?id=7a2f691d1b341690784fc9b2af6202feffdd50dfce2122abe8ad8bbddc6b53b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766754089,
      "headline": "Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access",
      "id": 137908167,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US price cuts, Medicare expansion, and new oral GLP-1 approvals reshape the competitive outlook for weight-loss drugs.",
      "url": "https://finnhub.io/api/news?id=7a2f691d1b341690784fc9b2af6202feffdd50dfce2122abe8ad8bbddc6b53b4"
    }
  },
  {
    "ts": null,
    "headline": "ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly",
    "summary": "ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company (\"Lilly\").",
    "url": "https://finnhub.io/api/news?id=23143f5fbe00094b3a938178ff583ef5e47fe27b6a23098dbe20909c59c48f5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766724900,
      "headline": "ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly",
      "id": 137906043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company (\"Lilly\").",
      "url": "https://finnhub.io/api/news?id=23143f5fbe00094b3a938178ff583ef5e47fe27b6a23098dbe20909c59c48f5b"
    }
  }
]